DongKoo Bio & Pharma Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	230,705	230,348	248,515	215,064	194,496	155,131
Other Revenue	10,729	12,339	760.23	622	491.86	17.86
Revenue	241,434	242,688	249,275	215,686	194,988	155,149
Revenue Growth	-0.46%	-2.64%	15.57%	10.62%	25.68%	11.45%
Cost of Revenue	101,704	98,346	97,388	83,610	77,128	62,812
Gross Profit	139,730	144,342	151,887	132,076	117,860	92,337
Selling, General & Admin	127,374	122,906	129,715	105,675	91,394	72,852
Research & Development	10,657	10,790	8,380	10,752	8,258	10,114
Amortization of Goodwill & Intangibles	180.08	185.43	182.86	144.88	124.77	109.81
Other Operating Expenses	304.63	292.07	375.81	203.67	273.54	282.42
Operating Expenses	139,391	135,095	139,197	117,460	101,023	84,198
Operating Income	339.04	9,248	12,691	14,616	16,836	8,139
Interest Expense	-3,816	-3,509	-2,894	-1,760	-1,039	-415.63
Interest & Investment Income	213.57	176.76	224.42	310.5	179.43	50.88
Currency Exchange Gain (Loss)	189.8	71.22	93.19	20.79	30.37	101.41
Other Non Operating Income (Expenses)	19,101	16,447	505.2	287.04	956.37	4,102
EBT Excluding Unusual Items	16,027	22,434	10,619	13,474	16,963	11,978
Gain (Loss) on Sale of Investments	41,657	52,550	-10,584	2,881	4,501	1,827
Gain (Loss) on Sale of Assets	1,357	1,023	7,114	401.74	136.72	2,258
Asset Writedown	-16,105	-14,595	-3,331	-2,016	-13,685	-4,728
Pretax Income	42,936	61,413	3,819	14,741	7,916	11,333
Income Tax Expense	10,055	11,240	1,828	2,932	1,302	2,007
Earnings From Continuing Operations	32,881	50,172	1,991	11,808	6,614	9,327
Minority Interest in Earnings	132.37	100.1	44.78	3.17	-	-
Net Income	33,013	50,272	2,036	11,812	6,614	9,327
Net Income to Common	33,013	50,272	2,036	11,812	6,614	9,327
Net Income Growth	453.61%	2369.74%	-82.77%	78.59%	-29.09%	2.04%
Shares Outstanding (Basic)	27	27	27	28	28	28
Shares Outstanding (Diluted)	28	28	27	28	28	28
Shares Change	1.72%	3.59%	-1.74%	-0.48%	-1.78%	-0.12%
EPS (Basic)	1222.17	1859.04	75.00	427.63	238.29	330.05
EPS (Diluted)	1191.87	1791.00	75.00	427.63	238.29	330.05
EPS Growth	445.58%	2288.00%	-82.46%	79.46%	-27.80%	2.16%

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-507.99	-21,944	-4,522	-10,260	11,841	13,637
Free Cash Flow Per Share	-18.30	-780.52	-166.62	-371.44	426.63	482.57
Gross Margin	57.88%	59.48%	60.93%	61.23%	60.45%	59.51%
Operating Margin	0.14%	3.81%	5.09%	6.78%	8.63%	5.25%
Profit Margin	13.67%	20.71%	0.82%	5.48%	3.39%	6.01%
Free Cash Flow Margin	-0.21%	-9.04%	-1.81%	-4.76%	6.07%	8.79%
EBITDA	8,616	18,166	19,964	20,644	22,469	13,193
EBITDA Margin	3.57%	7.49%	8.01%	9.57%	11.52%	8.50%
D&A For EBITDA	8,277	8,919	7,274	6,028	5,632	5,054
EBIT	339.04	9,248	12,691	14,616	16,836	8,139
EBIT Margin	0.14%	3.81%	5.09%	6.78%	8.63%	5.25%
Effective Tax Rate	23.42%	18.30%	47.87%	19.89%	16.44%	17.71%
Advertising Expenses	-	1,820	2,848	1,595	1,630	1,971